BioWorld

Jan. 23, 2004

View Archived Issues

Bringing In IL13 Phase III Trial Support, NeoPharm Gets $68.4M

NeoPharm Inc. intends to use proceeds from a $68.4 million public offering to advance its cancer agent for malignant glioma. (BioWorld Today) Read More

Genaera Gains $20M Through Direct Stock Equity Placement

Read More

Childhood Brain Tumor Growth With Neurofibromatosis Needs Abnormal Cellular Neighbors In Mouse Model

Read More

NIH Director In Senate Hot Seat Over Employee Disclosure Rules

Read More

Other News To Note

Read More